ARROWHEAD PHARMACEUTICALS, INC. Annual Share-based Payment Arrangement, Expense in USD from 2011 to 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Arrowhead Pharmaceuticals, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2011 to 2024.
  • Arrowhead Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $18.1M, a 0.37% decline year-over-year.
  • Arrowhead Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $67.1M, a 14.1% decline year-over-year.
  • Arrowhead Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $67.1M, a 14.1% decline from 2023.
  • Arrowhead Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $78.1M, a 35.4% decline from 2022.
  • Arrowhead Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $121M.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $67.1M -$11M -14.1% Oct 1, 2023 Sep 30, 2024 10-K 2024-11-26
2023 $78.1M -$42.8M -35.4% Oct 1, 2022 Sep 30, 2023 10-K 2024-11-26
2022 $121M Oct 1, 2021 Sep 30, 2022 10-K 2024-11-26
2017 $7.89M -$3.7M -31.9% Oct 1, 2016 Sep 30, 2017 10-K 2017-12-12
2016 $11.6M +$1.36M +13.3% Oct 1, 2015 Sep 30, 2016 10-K 2017-12-12
2015 $10.2M +$4.54M +79.6% Oct 1, 2014 Sep 30, 2015 10-K 2017-12-12
2014 $5.7M +$4.16M +271% Oct 1, 2013 Sep 30, 2014 10-K 2016-12-14
2013 $1.54M +$295K +23.8% Oct 1, 2012 Sep 30, 2013 10-K 2015-12-14
2012 $1.24M -$136K -9.84% Oct 1, 2011 Sep 30, 2012 10-K 2013-12-18
2011 $1.38M Oct 1, 2010 Sep 30, 2011 10-K 2012-12-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.